Seeking Alpha

Alcobra announces positive results from pre-clinical studies of of its autism treatment MG01C1

  • Alcobra (ADHD +5.6%) gains after announcing positive findings from a pre-clinical study of MG01CI in a mouse model of Fragile X Syndrome.
  • The study showed "significant" improvement in both cognitive and social functioning following treatment.
  • Fragile X syndrome is the most common single-gene cause of autism and inherited cause of intellectual disability among boys.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: